Literature DB >> 25652516

Assessment of potential advantages of relevant ions for particle therapy: a model based study.

Rebecca Grün1, Thomas Friedrich2, Michael Krämer2, Klemens Zink3, Marco Durante4, Rita Engenhart-Cabillic5, Michael Scholz2.   

Abstract

PURPOSE: Different ion types offer different physical and biological advantages for therapeutic applications. The purpose of this work is to assess the advantages of the most commonly used ions in particle therapy, i.e., carbon ((12)C), helium ((4)He), and protons ((1)H) for different treatment scenarios.
METHODS: A treatment planning analysis based on idealized target geometries was performed using the treatment planning software TRiP98. For the prediction of the relative biological effectiveness (RBE) that is required for biological optimization in treatment planning the local effect model (LEM IV) was used. To compare the three ion types, the peak-to-entrance ratio (PER) was determined for the physical dose (PERPHY S), the RBE (PERRBE), and the RBE-weighted dose (PERBIO) resulting for different dose-levels, field configurations, and tissue types. Further, the dose contribution to artificial organs at risk (OAR) was assessed and a comparison of the dose distribution for the different ion types was performed for a patient with chordoma of the skull base.
RESULTS: The study showed that the advantages of the ions depend on the physical and biological properties and the interplay of both. In the case of protons, the consideration of a variable RBE instead of the clinically applied generic RBE of 1.1 indicates an advantage in terms of an increased PERRBE for the analyzed configurations. Due to the fact that protons show a somewhat better PERPHY S compared to helium and carbon ions whereas helium shows a higher PERRBE compared to protons, both protons and helium ions show a similar RBE-weighted dose distribution. Carbon ions show the largest variation of the PERRBE with tissue type and a benefit for radioresistant tumor types due to their higher LET. Furthermore, in the case of a two-field irradiation, an additional gain in terms of PERBIO is observed when using an orthogonal field configuration for carbon ions as compared to opposing fields. In contrast, for protons, the PERBIO is almost independent on the field configuration. Concerning the artificial lateral OAR, the volume receiving 20% of the prescribed RBE-weighted dose (V20) was reduced by over 35% using helium ions and by over 40% using carbon ions compared to protons. The analysis of the patient plan showed that protons, helium, and carbon ions are similar in terms of target coverage whereas the dose to the surrounding tissue is increasing from carbon ions toward protons. The mean dose to the brain stem can be reduced by more than 55% when using helium ions and by further 25% when using carbon ions instead of protons.
CONCLUSIONS: The comparison of the PERRBE and PERPHY S of the three ion types suggests a strong dependence of the advantages of the three ions on the dose-level, tissue type, and field configuration. In terms of conformity, i.e., dose to the normal tissue, a clear gain is expected using carbon or helium ions compared to protons.

Entities:  

Mesh:

Year:  2015        PMID: 25652516     DOI: 10.1118/1.4905374

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  13 in total

1.  Does a too risk-averse approach to the implementation of new radiotherapy technologies delay their clinical use?

Authors:  R Garcia; H Nyström; C Fiorino; D Thwaites
Journal:  Br J Radiol       Date:  2015-05-20       Impact factor: 3.039

2.  Comparative Risk Predictions of Second Cancers After Carbon-Ion Therapy Versus Proton Therapy.

Authors:  John G Eley; Thomas Friedrich; Kenneth L Homann; Rebecca M Howell; Michael Scholz; Marco Durante; Wayne D Newhauser
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-16       Impact factor: 7.038

3.  Scanned ion beam therapy for prostate carcinoma: Comparison of single plan treatment and daily plan-adapted treatment.

Authors:  Sebastian Hild; Christian Graeff; Antoni Rucinski; Klemens Zink; Gregor Habl; Marco Durante; Klaus Herfarth; Christoph Bert
Journal:  Strahlenther Onkol       Date:  2015-11-27       Impact factor: 3.621

4.  New Ions for Therapy.

Authors:  Francesco Tommasino; Emanuele Scifoni; Marco Durante
Journal:  Int J Part Ther       Date:  2016-02-09

Review 5.  Effects of Charged Particles on Human Tumor Cells.

Authors:  Kathryn D Held; Hidemasa Kawamura; Takuya Kaminuma; Athena Evalour S Paz; Yukari Yoshida; Qi Liu; Henning Willers; Akihisa Takahashi
Journal:  Front Oncol       Date:  2016-02-12       Impact factor: 6.244

6.  Proton and helium ion radiotherapy for meningioma tumors: a Monte Carlo-based treatment planning comparison.

Authors:  Thomas Tessonnier; Andrea Mairani; Wenjing Chen; Paola Sala; Francesco Cerutti; Alfredo Ferrari; Thomas Haberer; Jürgen Debus; Katia Parodi
Journal:  Radiat Oncol       Date:  2018-01-09       Impact factor: 3.481

7.  A Simpler Energy Transfer Efficiency Model to Predict Relative Biological Effect for Protons and Heavier Ions.

Authors:  Bleddyn Jones
Journal:  Front Oncol       Date:  2015-08-11       Impact factor: 6.244

Review 8.  Differential Superiority of Heavy Charged-Particle Irradiation to X-Rays: Studies on Biological Effectiveness and Side Effect Mechanisms in Multicellular Tumor and Normal Tissue Models.

Authors:  Stefan Walenta; Wolfgang Mueller-Klieser
Journal:  Front Oncol       Date:  2016-02-25       Impact factor: 6.244

Review 9.  The Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial Lesions.

Authors:  Aaron Michael Laine; Arnold Pompos; Robert Timmerman; Steve Jiang; Michael D Story; David Pistenmaa; Hak Choy
Journal:  Front Oncol       Date:  2016-01-11       Impact factor: 6.244

10.  Next generation multi-scale biophysical characterization of high precision cancer particle radiotherapy using clinical proton, helium-, carbon- and oxygen ion beams.

Authors:  Ivana Dokic; Andrea Mairani; Martin Niklas; Ferdinand Zimmermann; Naved Chaudhri; Damir Krunic; Thomas Tessonnier; Alfredo Ferrari; Katia Parodi; Oliver Jäkel; Jürgen Debus; Thomas Haberer; Amir Abdollahi
Journal:  Oncotarget       Date:  2016-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.